Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Thank you Buddyboy. Yes, this topic is interestin

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154604
(Total Views: 618)
Posted On: 10/01/2022 9:20:20 PM
Posted By: MGK_2
Re: Buddyboy20 #129175
Thank you Buddyboy. Yes, this topic is interesting.

I don't see how the current data set could be negligent as it is currently being aggregated into the appropriate FDA approved format. That was the document that was prepared in September, with the remaining series of document to be prepared and sent to the FDA as quickly as they can as per Cyrus.

In previous conference call, Scott Kelly said, I want you to be clear, we have the data, it is just not in the right format.

So for 6 months, Recknor and company have been going through the Amarex trials and aggregating the data into the FDA approved format, on excel sheets instead of paper, etc...

Once the FDA receives all the documents in the series, they will go through the complete aggregation of all the safety data on leronlimab across all the trials that Amarex did and then a determination as to how safe leronlimab will be made based on this work and then the hold will be lifted. I'm thinking Thanksgiving and I believe Emmitt was thinking the same, but I could be wrong.

Certainly, if leronlimab is not shown to be safe by the re-aggregated data, the hold won't be lifted and the BLA would subsequently not be re-submitted, but that won't happen.

The GCP Audit will show that had Amarex done what they were contracted to do, to prepare and submit an acceptable BLA to the FDA, then the FDA would have accepted the BLA and subsequently, leronlimab would have likely been approved by the FDA.

With this positive result, CytoDyn will decide to re-assemble the BLA and re-submit the BLA for HIV by end of year.

I'm not sure how Rantes is getting dollar values from any of this though.


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us